The FDA has given a green light to a hydrogel applicator that can be quickly deployed to help stem severe, life-threatening bleeding within seconds.

At Bayer, a groupwide restructuring is being rolled out as a top priority. But, to Juergen Eckhardt, M.D., who leads both the investment arm Leaps by Bayer and the pharma business development team, the ongoing overhaul won’t disrupt the German company’s dealmaking appetite.

After collecting a de novo clearance from the FDA last fall for its ultrasound-powered liver cancer treatment, HistoSonics has raised $102 million in funds to turn up the volume on its commercial efforts.

Céline Dion stands alone as a singer, a chart-topping ballad-belter who recorded some of the most iconic songs of all time, including “My Heart Will Go On” from the “Titanic” soundtrack. But, in 2022, Dion made headlines not for her one-in-a-million voice, but for a one-in-a-million diagnosis: a rare neurological disease called stiff-person syndrome (SPS).

Researchers at UC Davis have used a brain-computer interface implant to help restore a patient’s voice, after ALS had slowly robbed him of his ability to speak clearly.

In 1933, geneticist Thomas Hunt Morgan won the Nobel Prize in Physiology or Medicine for demonstrating that genes exist on chromosomes, which are passed down from parent to offspring. Ninety-one years later, researchers at Columbia University—the same school where Morgan conducted his award-winning fruit fly research—have found a gene that violates this cardinal rule.

After Arrowhead Pharmaceuticals cleared out its work on a clinical-stage cardiovascular candidate, the company is filling the blank space with two obesity assets, both set to enter the clinic in early 2025.

Antisense oligonucleotides (ASOs), which bind to RNA and prevent them from being translated into proteins, have gained popularity in recent years as a way to treat neurodegenerative diseases. However, getting these drugs into the brain has been challenging, currently requiring invasive infusion directly into the cerebrospinal fluid.

Designing a clinical trial is hard work. Silicon Valley tech company Medable is hoping to make it easier with their newly launched Medable Studio, an all-in-one platform for configuring, translating, validating and launching Medable’s software solution into clinical trials.

Kezar Life Sciences is dropping its unpromising phase 1 solid tumor drug as the biotech goes all-in on its lead autoimmune hepatitis program.